Editas Medicine News and Activities
Presence
Editas Medicine develops gene editing medicines. It provides research, drug development, and therapy programs for hospitals, researchers, and patients with serious genetic and eye diseases.
Editas Medicine products and services overview:
- Gene editing therapies
- Cell therapy research
- Eye disease treatments
- Genetic disease programs
- Drug discovery services
Revenue: ~$28 million
Employees: 230
Headquarters: Cambridge, United States (USA)
Editas Medicine is one of the...
Editas Medicine is a company listed under the stock ticker EDIT (US).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Editas Medicine
- Gilmore O'Neill, Chief Executive Officer and President
- David Scadden, Director
- Andrew Hirsch, Director
Popular executive movements at Editas Medicine
- Linea Aspesi, Executive Vice President and Chief People Officer, has left the company (posted on October 6 2025).
Create your alert
to follow the executive moves at Editas Medicine.
Biotechnology
Editas Medicine has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Editas Medicine
- Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | Editas Medicine
- Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference | Editas Medicine
- Editas Medicine Announces Proposed Public Offering | Editas Medicine
- Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress | Editas Medicine
- Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | Editas Medicine
- Editas Medicine Announces First Quarter 2026 Results and Business Updates | Editas Medicine
- Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences | Editas Medicine
- Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | Editas Medicine
- Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Editas Medicine
- Editas Medicine to Participate in Upcoming Investor Conferences | Editas Medicine
- View more press releases Close
Social media about Editas Medicine
- Editas Medicine on Wikipedia, Google News & Yahoo Finance
- Editas Medicine on LinkedIn, X (Twitter) & YouTube
